The acetylcholinesterase knockout mouse has elevated acetylcholine levels due to the complete absence of acetylcholinesterase. Our goal was to determine the adaptive changes in lung receptors that allow these animals to tolerate excess neurotransmitter. The hypothesis was tested that not only muscarinic receptors but also alpha(1)-adrenoceptors and beta-adrenoceptors are downregulated, thus maintaining a proper balance of receptors and accounting for lung function in these animals. The quantity of alpha(1A), alpha(1B), alpha(1D), beta(1), and beta(2)-adrenoceptors and muscarinic receptors was determined by binding of radioligands. G-protein coupling was assessed using pseudo-competition with agonists. Phospholipase C activity was measured by an enzymatic assay. Cyclic AMP (cAMP) content was measured by immunoassay. Muscarinic receptors were decreased to 50%, alpha(1)-adrenoceptors to 23%, and beta-adrenoceptors to about 50% of control. Changes were subtype specific, as alpha(1A), alpha(1B), and beta(2)-adrenoceptors, but not alpha(1D)-adrenoceptor, were decreased. In contrast, receptor signaling into the cell as measured by coupling to G proteins, cAMP content, and PI-phospholipase C activity was the same as in control. This shows that the nearly normal lung function of these animals was explained by maintenance of a correct balance of adrenoceptors and muscarinic receptors. In conclusion, knockout mice have adapted to high concentrations of acetylcholine by downregulating receptors that bind acetylcholine, as well as by downregulating receptors that oppose the action of muscarinic receptors. Tolerance to excess acetylcholine is achieved by reducing the levels of muscarinic receptors and adrenoceptors.

Institute of Physiology 1st Faculty of Medicine Charles University Albertov 5 12800 Prague Czech Republic

Zobrazit více v PubMed

Pharmacol Ther. 1990;48(3):295-322 PubMed

Ann Neurol. 2003 Jun;53(6):788-96 PubMed

Trends Neurosci. 2006 Mar;29(3):140-7 PubMed

Am J Physiol. 1997 Sep;273(3 Pt 1):G586-601 PubMed

J Biol Chem. 2004 Nov 5;279(45):46882-9 PubMed

Pharmacol Ther. 2006 Jul;111(1):260-71 PubMed

J Mol Neurosci. 2006;30(1-2):69-70 PubMed

Mol Cell Neurosci. 2003 May;23(1):121-33 PubMed

J Pharmacol Exp Ther. 2000 Jun;293(3):896-902 PubMed

Biochem Pharmacol. 1998 May 1;55(9):1419-26 PubMed

Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 3):S154-60 PubMed

Mol Pharmacol. 2003 Dec;64(6):1309-16 PubMed

Physiol Rev. 1999 Oct;79(4):1373-430 PubMed

Anal Biochem. 1977 Dec;83(2):346-56 PubMed

Muscle Nerve. 2004 Sep;30(3):317-27 PubMed

Life Sci. 1996 May 24;58(26):2423-30 PubMed

Eur Respir J. 2000 Jun;15(6):1120-7 PubMed

Eur J Neurosci. 2003 Sep;18(6):1419-27 PubMed

Life Sci. 2006 Jun 6;79(2):112-20 PubMed

J Comp Neurol. 2003 Jun 9;462(3):302-14 PubMed

J Neurochem. 1999 Aug;73(2):780-90 PubMed

Brain Res Dev Brain Res. 2002 Jul 30;137(1):43-54 PubMed

Toxicol Appl Pharmacol. 1986 Jul;84(3):541-50 PubMed

Crit Care. 2002 Aug;6(4):335-41 PubMed

Neuroscience. 2004;125(4):1009-17 PubMed

J Pharmacol Exp Ther. 2001 Nov;299(2):528-35 PubMed

Respir Physiol Neurobiol. 2004 Jun 25;140(3):231-41 PubMed

Life Sci. 2006 Dec 3;80(1):17-23 PubMed

Pharmacol Biochem Behav. 2003 Mar;74(4):977-86 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2006 Nov;374(2):99-105 PubMed

Life Sci. 1997;60(13-14):1061-8 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):366-76 PubMed

Toxicology. 1982;25(2-3):79-97 PubMed

J Neurochem. 2007 Mar;100(5):1421-9 PubMed

Biochem Pharmacol. 2003 Sep 15;66(6):1067-81 PubMed

Adv Exp Med Biol. 2004;551:165-70 PubMed

Developmental adaptation of central nervous system to extremely high acetylcholine levels

Decrease in heart adrenoceptor gene expression and receptor number as compensatory tool for preserved heart function and biological rhythm in M(2) KO animals